

Jill M. Kolesar, PharmD, MS, BCPS, FCCP

University Research Professor, College of Pharmacy, Department of Pharmacy Practice and Science,
University of Kentucky

Dr. Michael Karpf Endowed Chair in Precision Medicine

Co-Leader, Translational Oncology Research Program, Markey Cancer Center

[Linkedin.com/in/jill-kolesar](https://www.linkedin.com/in/jill-kolesar)

jill.kolesar@uky.edu

(608) 239-0460

Website: <https://scholars.uky.edu>

EXECUTIVE SUMMARY OF CURRICULUM VITAE

Academic Leader, Educator and Translational Researcher with proven ability to translate research from bench to clinic to community. Strengths in cancer clinical pharmacology, drug development and precision medicine research. Innovative leader known for “connecting the dots” when establishing transdisciplinary and inter-professional collaborations. Adept at leveraging research resources, stewarding translational pipelines and fostering collegiality and collaboration. Passion for mentoring undergraduates to junior faculty and fostering team science, education and practice models. National leader in oncology pharmacy precision medicine practice transformation and education.

ACADEMIC LEADERSHIP EXPERIENCE

- 20+ years of academic leadership experience in NCI designated matrix cancer centers, currently co-lead Translational Oncology Research Program
- Foster collaborations among 65 faculty from 5 colleges, oversee a staff of 24, \$2.7 annual operating budget and >\$10M research portfolio
- Primary responsibilities include: faculty, staff and trainee recruitment and development, community outreach and engagement, administration of pilot funding programs, research and clinical program implementation, all with a goal of fostering translational team science
- Over the last 5 years:
 - Successfully contributed to Markey obtaining Comprehensive Cancer Center Designation
 - Increased annual program funding from \$5.6M (direct) to more than \$10M
 - Implemented and oversee the following programs; Early Phase Clinical Trials Precision Medicine Center (3 National Patient Experience Awards); a state-wide, pharmacist-led Molecular Tumor Board (> 3000 cases reviewed, more than 15 community practices engaged), Oncology Research Information Exchange Network (ORIEN) membership and leadership (vice-chair of Steering Committee)

RESEARCH & INTELLECTUAL CONTRIBUTIONS

- \$12.9M in current active funding from NIH, foundations and industry as the Principal Investigator or MPI
- Over 150 peer-reviewed original research papers and more than 250 additional review articles, editorials, letters and abstracts. Full list of published work available at: [Jill Kolesar - Google Scholar](#)
- 9 patents or patents pending and two start-up companies, Helix Diagnostics and VesiCure Technologies
- H-index (Jan 2024): Google Scholar: 48, i10-index 165, 8340 citations, Scopus: 39, 5315 citations
- 13 years experience oversight GLP laboratory; 1 year experience in cell-based therapy GMP manufacturing

DIVERSITY AND INCLUSIVITY CONTRIBUTIONS

- Active recruitment of faculty, staff, students and postdocs from diverse backgrounds
- Sustained contributions to ACTION, a career training program for disadvantaged high school and undergraduate students from Appalachian Kentucky
- Ongoing efforts to overcome barriers to precision medicine implementation in rural communities
- National advocacy efforts to advance women in pharmacy leadership
- Founding co-chair, Diversity, Equity and Inclusivity Research Interest Group for ORIEN

MENTORING, TEACHING and ACADEMIC SERVICE

- Primary mentor for more than 60 prior and current interprofessional mentees (PharmD, MD), high school to junior faculty, many going on to academic positions and NIH funded via multiple mechanisms including COBRE, T32 and NCI training grants
- 20+ years of experience in didactic teaching, experiential education and academic service
- American Association of Colleges of Pharmacy Innovation in Teaching Award
- 15+ years of experiencing editing leading pharmacy textbooks, Pharmacotherapy Principles and Practice, Top 300 Pharmacy, Top 200 Injectables and Top 100 Over the Counter Medication Flash Cards

EDUCATION

University of Wisconsin - Madison, School of Pharmacy

Bachelor of Science, May 1990

University of Texas Health Science Center and The University of Texas at Austin, College of Pharmacy

Doctor of Pharmacy, May 1994

Medical Center Hospital (Concurrent with PharmD)

Specialized Residency, Oncology/Hematology, July 1993 - December 1993

The University of Texas Health Science Center

Fellowship, Oncology/Hematology Fellowship, January 1994 - June 1996

University of Wisconsin School of Medicine and Public Health

Master of Science, Epidemiology (Genetic Epidemiology Minor), December 2015

PROFESSIONAL LICENSURE AND CERTIFICATION

DEA registration # RK0525735

2016 - present

Wisconsin # 12783

1998 - present

Board Certified Pharmacotherapy Specialist (BCPS)

1996 - 2023

Texas # 32667

1991 - present

PROFESSIONAL DEVELOPMENT

I-RED Program Coaching Program

the XLerator Network Dec 1, 2023-current

NSF Regional I-Corps UK Fall 2023 Cohort

Certificate, September 2023- November 2023

I-RED Program, SBIR 1:1 Coaching Program

the XLerator Network June 1, 2023-September 31, 2023

University of Kentucky, Women's Executive Leadership Development Program (WELD)

Certificate, September 2019 – September 2021

National Cancer Institute, Training Institute for Dissemination and Implementation in Cancer

Certificate, July 2017 - July 2018

University of Minnesota, School of Pharmacy

Mini-Sabbatical, Population Pharmacokinetic Modeling, September 2008-December 2008

TECHNICAL SKILLS

Education Technology: Canvas | Moodle | Access Pharmacy

Research Technology: Oncore | REDcap | Labkey | SAS | R | Lab Notebook | Cayuse

Healthcare Technology: EPIC | Allscripts

CHRONOLOGICAL PROFESSIONAL EXPERIENCE

Founder and Chief Executive Officer

July 2023-present

VesiCure Technologies

Lexington, Kentucky

Dr. Michael E. Karpf Endowed Chair in Precision Medicine

July 2022-present

Markey Cancer Center
University of Kentucky

University Research Professor (tenured) September 2021- present
College of Pharmacy, Department of Pharmacy Practice and Science
College of Medicine, Department of Gynecology and Oncology, Division of Gynecological Oncology
University of Kentucky

Adjunct Faculty July 2021 - present
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Manipal Academy of Higher Education

Professor (tenured) October 2016 - present
College of Pharmacy, Department of Pharmacy Practice and Science
College of Medicine, Department of Gynecology and Oncology, Division of Gynecological Oncology
University of Kentucky

Professor (CHS) March 2009 - October 2016
School of Pharmacy, Division of Pharmacy Practice
University of Wisconsin-Madison

Associate Professor (CHS) July 2002 - March 2009
School of Pharmacy, Division of Pharmacy Practice
University of Wisconsin-Madison

Assistant Professor (CHS) July 1996 - October 2002
School of Pharmacy, Division of Pharmacy Practice
University of Wisconsin-Madison

Academic Clinical Pharmacist (20%) July 1996 - July 2012
Hematology Clinic, William S. Middleton VA Hospital

Administrative Fellow July 1995 - June 1996
Division of Clinical Pharmacy, College of Pharmacy
The University of Texas Health Science Center and The University of Texas at Austin

Chief Resident July 1995 - June 1996
Division of Clinical Pharmacy, College of Pharmacy
The University of Texas Health Science Center and The University of Texas at Austin

Clinical Instructor July 1995 - June 1996
Division of Clinical Pharmacy, College of Pharmacy
The University of Texas Health Science Center and The University of Texas at Austin

ACADEMIC LEADERSHIP EXPERIENCE (CONCURRENT WITH ACADEMIC APPOINTMENTS)

Markey Cancer Center (University of Kentucky) October 2016 - present
Co-Leader Translational Oncology (TO) Research Program

- ❖ **Supervision:** Oversee a staff of 24 FTE with 5 direct reports including a leadership team consisting of an Assistant Director, Nurse Manager, Nurse Navigator, Chief of Staff and PhD Scientist that manages program infrastructure.
- ❖ **Direct annual budget:** \$2.74M
- ❖ **Research portfolio oversight:** >\$10M
- ❖ **National Cancer Institute Cancer Center Application Outcomes** over last 5 years:
 - Increased program funding from \$5.6M (direct) to more than \$10M
 - Improved annual therapeutic accrual from 138 patients to 345 patients
 - Improved annual publications of TO member from 76 publications to 136 publications
 - Improved program score from Excellent to Very Good in 2018 to Outstanding to Excellent in 2023

Key Responsibilities: Facilitate, advance, and oversee transdisciplinary research collaborations between clinical and research scientists, including 65 faculty researchers across 5 university colleges: pharmacy, medicine, engineering, veterinary, and arts & sciences. Manage the translation of research from the bench to the bedside, specifically focused on moving new and re-purposed anti cancer agents from the lab into clinical trials. Organize and lead program retreats, and facilitate introduction to shared services. Responsible for developing, writing, and submitting TO section of NCI applications, including annual reporting and external advisory board presentations.

Significant Program Development:

- **Fundraising**
 - Speaker at frequent donor engagements on behalf of Markey Cancer Center. Present research advances to donors including Breath of *Hope Kentucky*, *Markey Foundation*, and *Markey Women Strong*.
 - Annual fundraising gifts exceed \$5M
 - Serve as Campaign spokesperson for *Kentucky Can: The 21st Century Campaign, University of Kentucky* which raised \$2.1B
 - Advised State Representative Kim Moser on developing a state house bill in support of cancer biomarker testing
- **Molecular Tumor Board**
 - Established and grew highly-regarded state-wide Molecular Tumor Board (MTBs) with >3K cases reviewed
 - Demonstrated the clinical benefit of pharmacist-led MTB review, a practice that has become the MTB standard, and has led to practice transformation across the state
 - Established an interprofessional certificate program in Oncology Precision Medicine, which has trained 350 health professionals over the last 3 years
- **Early Phase Clinical Trials Center**
 - Established a National Cancer Institute-Supported Early Phase Clinical Trials Center with an increase in early phase therapeutic annual accrual from 18 patients to 220 patients over 7 years
 - Develop, review, implement and oversee clinical protocols for ongoing Translational Oncology Research Program, increasing overall annual accrual from 138 patients to 400 patients in 7 years
- **ORIEN – National Clinical and Genomic Data Sharing Network**
 - Joined ORIEN Network, enrolled over 10,000 participants on Total Cancer Care, focusing on catchment-relevant cancers and increasing representation of our catchment area’s historically under-represented rural disparate population in genomic repositories
 - TO members lead 8 inter-member ORIEN network projects and participate in 25+ projects led by others, with 4 publications to date

UW Carbone Comprehensive Cancer Center

July 2003 – October 2016

Faculty Supervisor, Analytical Instrumentation Laboratory Shared Service

- ❖ **Supervision:** Oversee a staff of 4 FTE, 1 direct report
- ❖ **Annual budget oversight:** \$500K
- ❖ **National Cancer Institute Cancer Center Application Outcomes:**
 - Improved evaluation of shared service from Excellent-Very Good to Outstanding-Exceptional
 - Grew suite of services to include pharmacogenomics, GLP, and biomarker analysis

Key Responsibilities: Supervised a Shared Service Laboratory and oversaw clinical pharmacology assay development, validation and performance in clinical trials. Performed pharmacokinetic data analysis. Mentored junior investigators on inclusion of bio markers into clinical trials. Responsible for developing, writing, and submitting Shared Service Facility section of NCI applications, including annual reporting and external advisory board presentations.

Significant Program Development:

- **Fundraising**
 - Developed relationship with founder and staff of Jody Lou Foundation, attending events and speaking on behalf of UW Carbone Comprehensive Cancer Center
 - Annual gifts: \$30,000-\$50,000
- **Molecular Tumor Board**
 - Established and championed a statewide Molecular Tumor Board (MTBs) with > 100 cases reviewed in first year

- Led Practice Transformation within MTB structure

HONORS AND AWARDS

2023	Power of Women Honoree, University of Kentucky
2022 - present	Dr. Michael Karpf Endowed Chair in Precision Medicine at the Markey Cancer Center
2021 - present	University Research Professor, University of Kentucky
2017 - present	Wethington Award for Research Excellence, University of Kentucky
2011	Teacher of the Year Award, UW School of Pharmacy
2003	Best Abstract – 8th International Congress on Advances in Molecular Medicine
2002	Fellow, American College of Clinical Pharmacy
2001	Innovations in Teaching Award, American Association of Colleges of Pharmacy
2000	Research Award, International Society of Oncology Pharmacy Practitioners
1998	Rho Chi Society
1996	Merit Award Recipient, American Society of Clinical Oncology
1995	ACCP/Rhone-Poulenc Rorer Fellowship in Oncology
1992	Phi Kappa Phi National Honor Society
1988 - 1990	Honor roll, University of Wisconsin

RESEARCH & INTELLECTUAL CONTRIBUTIONS

- **\$12.9M** in current active funding from NIH, foundations and industry as the Principal Investigator
- Over **150** peer-reviewed original research papers and more than **200** additional review articles, editorials, letters and abstracts published in professional and scientific journals on topics related to clinical pharmacology, clinical trials, cancer therapy and cancer precision medicine. Full list of published work available at: [Jill Kolesar - Google Scholar](#)
- **H-index (January 2024)**
 Google Scholar: 48, i10-index 165, 8340 citations
 Scopus: 39, 5315 citations
- 9 patents or patents pending and two start-up companies, Helix Diagnostics and VesiCure Technologies
- 3 research awards from professional societies, awarded both University Research Professor and endowed chair

Patents and Entrepreneurial Activity-Trainees are underlined

1. **Kolesar JM**. Analysis of mutations by direct detection of nucleic acids with CE-LIF. Patent #6,261,781 issued on 7/17/01.
Founded Helix Diagnostics, Inc. in July 2001 based on this technology.
2. **Kolesar JM**, Allen PA. Direct Detection of mRNA. Patent #6,013,442 issued 1/11/00
Founded Helix Diagnostics, Inc. in July 2001 based on this technology.
3. Xu W, Tang W, Liu J, **Kolesar J**. Synthesis of novel analogs of diptoindonesin g, compounds formed thereby, and Pharmaceutical compositions containing them. Patent #10,508,092 issued 12/17/19
4. Richards C and **Kolesar JM**. Cell derived vesicles via membrane fragmentation for targeted therapeutic delivery. #13177N/2267US Feb 10, 2021 by the UK Research Foundation.
Founded VesiCure Technologies in July 2023 based on this technology.
5. Berry S and **Kolesar J**. Method for Quantifying 5-FU Drug in Plasma at Point-of-Care. Serial No. 63/213,572 filed on June 22, 2021 by UK Research Foundation
6. **Kolesar J**, Ueland F, Hill K, McDowell A, Maust A, Gilmore K, Seeberger P. Anticancer Activity of Artemesia Derivatives. **Current Status:** Filed: 17/928,858 US, Nov 11, 2022; CA3,185,011, Canada June 2, 2021; EP

21818653.4, Europe June 2, 2021, JP 2022-574514, Japan June 2, 2021; MX/a/222/015275m, Mexico June 2, 2021.

Licensed to ArtemiLife Jan 2023

7. **Kolesar JM, Riggs MK, Lin N, Ueland F.** DACH1 Mutations as a Predictor of Immunotherapy. Serial No. 63/272,071 filed on October 26, 2021.
8. **Kolesar JM** and Richards C. Dendritic cell-derived vesicles and activation of antigen-specific t-cells 13177N/20230105 US Jan 5, 2024 by the UK Research Foundation.
Founded VesiCure Technologies in July 2023 based on this technology
9. **Richards C.** and Kolesar JM Programming Cell-Derived Vesicles with Enhanced Immunomodulatory Properties. Disclosed Oct 18, 2023 to UK Research Foundation
Founded VesiCure Technologies in July 2023 based on this technology

Active Funding- Principal Investigator or MPI-External

1. No ID	9/1/22-8/31/27	\$3,796,000
PRiMAL: Precision Medicine Randomized Clinical Trial of Molecular Tumor Board Assisted Care Funder: LOXO@Lilly Role: Principal Investigator		
2. 1R01CA258751-01A1	5/1/22-4/30/27	\$634,772
Combating melanoma resistance by targeting ABL1/2 Funder: NCI Role: Multi-Principal Investigator		
4. No ID	10/27/2020-7/1/2024	\$374,000
Evaluation of SARS-COV-2 Positivity and Genetic Risk in Cancer Patients Funder: M2GEN Foundation Role: Principal Investigator		
5. No ID	4/14/2020-12/13/2024	\$18,000
Assessing the Anticancer Activity of Artemesia Annua Funder: ArtemiLife Role: Principal Investigator		
6. PON2 728 200000247	07/01/20-06/30/24	\$857,491
Artesunate as a Novel Treatment for Childhood AML Funder: Kentucky Pediatric Cancer Research Trust Fund Role: Principal Investigator		
7. PON2 728 2000002500	07/01/20-06/30/24	\$629,000
Macrophage Derived Engineered Vesicles (MEDs) for Preventing Metastases in Pediatric Osteosarcoma Funder: Kentucky Pediatric Cancer Research Trust Fund Role: Principal Investigator		
8. PO2 415 1400004000 1	07/01/16-06/30/24	\$133,000
Utility of ctDNA in personalized therapy for non-small-cell lung cancer Funder: Kentucky Lung Cancer Research Program Role: Principal Investigator		
9.No ID	07/01/18-06/30/24	\$150,000
Assessing the Mechanism of Drug Resistance in Lung Cancer		

Funder: Kentucky Lung Cancer Research Program
Role: Principal Investigator

10.No ID	07/01/17-indefinite (cost center)	\$6,100,000
ORIEN Avatar Cost Assistance		
Funder: M2GEN		
Role: Principal Investigator		

Active Funding- External- Co-Investigator

1. P20 GM13045	03/01/20-01/31/25	\$11,207,708
COBRE in Pharmaceutical Research and Innovation		
Funder: NIH/NCATs		
Role: Mentor		

2. P30 CA177558	07/08/13-06/30/23	\$10,763,550
University of Kentucky Markey Cancer Center – Cancer Center Support Grant		
Funder: NIH		
Role: Co-Program Leader, Translational Oncology		

3. P30 CA177558-08S2	07/01/20-03/31/22	\$299,813
CCSG Supplement: Childhood Cancer Data Initiative (CCDI) National Childhood Cancer Registry (NCCR), University of Kentucky Markey Cancer Center - Cancer Center Support Grant.		
Funder: National Cancer Institute		
Role: Co-Investigator		

4. UM1CA186712	03/01/20-02/28/26	\$2,116,907
Experimental therapeutics of anti-cancer agents with Phase I emphasis		
Funder: NIH/NCI – Ohio State University subaward		
Role: Co-Investigator		

5. PON2 728 2000003191	07/01/20-06/30/22	\$664,604
Pediatric Molecular Tumor Board C2448: CL 1: FY21 Pediatric Molecular Tumor Board		
Funder: Kentucky Pediatric Cancer Research Trust Fund		
Role: Co-I		

Active Funding- Principal Investigator-Internal

1. No ID	7/1/22-2/38/23	\$39,964
Development of mitochondria targeting agents for ovarian cancer		
Funder: Office of the Vice President for Research		
Role: Principal Investigator		

2.No ID	7/1/22-6/30/23	\$81,500
Engineered Human Monocyte Vesicles for Personalized Cancer Therapy		
Funder: KYNETIC		
Role: Principal Investigator		

3. No ID	7/1/22-7/31/24	\$50,000
Novel Treatments for Ovarian Cancer		
Funder: Markey Cancer Center		
Role: Principal Investigator		

4. No ID	8/1/22-7/31/25	\$33,000
-----------------	-----------------------	-----------------

Genocare

Funder: Markey Cancer Center

Role: Principal Investigator

5. No ID

9/1/18-8/30/23

\$100,000

Implementing Precision Medicine in Family Medicine

Funder: College of Medicine Deans Office

Role: Principal Investigator

Summary of Completed Research Funding (*Therapeutic Clinical Trial)

	Title	Role	Funder	Dates	Amount (Total)
1	Administrative Supplement: Evaluation of deoxynucleosides as a novel resistance mechanism for radiotherapy	Principal Investigator	NIH/NCI – Ohio State University subaward	05/05/20-02/28/23	\$110,749
2	Implementing Cancer Precision Medicine in India	PI	NCI	04/01/20 - 03/30/22	\$36,560
3	Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky	Co-I	American Cancer Society	07/01/18 - 06/30/22	\$150,000
4	P30CA177558-07: Selection of Personalized Cancer Therapies by Evaluating Intra-tumoral Heterogeneity and Phylogenetic Analysis	PI	NCI	07/09/18 - 04/08/20	\$50,000
5	UM1CA186712-03: Experimental therapeutics of anti-cancer agents with Phase I emphasis	Co-I	NIH/NCI – Ohio State University subaward	03/28/16 - 02/28/20	\$110,000
6	Targeted separation of patient derived cells for high throughput generation of exosome-like vesicles for personalized medicine therapies	PI	UK IRC Pilot Project	7/6/17 - 6/30/18	\$50,000
7	Identification of novel therapeutics strategies for colorectal cancer based on genomic profiling	PI	UK IRC Pilot Project	7/6/17 - 6/30/18	\$50,000
8	Implementing Oncology Precision Medicine in Kentucky	PI	UK VI2P Pilot Project	7/6/17 - 12/23/18	\$150,000
9	1 UM1CA186716-01: Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics	Co-PI	NCI	03/19/14 - 02/28/16	\$158,000
10	W81XWH-14-2-0155: Prostate Cancer Clinical Trials Consortium	Co-I	DoD/Prostate Cancer Research Program	09/30/14 - 08/31/16	\$120,000
11	MITOS: Molecular Individualization of Therapy of NSCLC.	PI	University of Wisconsin Foundation	12/01/13 - 9/30/16	\$175,000
12	HHSN261201200033 Cancer Prevention against Development Program: Early Phase Clinical Research	Co-I	NIH/NCI	09/24/12 - 09/23/16	\$375,000
13	*Population Pharmacokinetics of Taxol and Carboplatin	PI	UWCCC	07/01/11 - 9/30/16	\$50,000
14	*UWME4508R-00: Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12	PI	NIH/NCI	06/01/09 - 05/31/12	\$79,000

	or Both for Advanced Non-small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy				
15	*UW4206JK-00: E4206: Assessment of Plasma VEGF	PI	NCI	09/16/08 - 12/1/14	\$42,411
16	*233-PRJ11EM: Molecular Markers of NSCLC	PI	University of Wisconsin Foundation	12/01/07 - 9/30/16	\$50,000
17	*UW3503JK-00: Development of a Model to Predict Progression-free Survival Model after Treatment with Erlotinib in E3503	PI	NCI	04/13/07 - 12/1/14	\$14,720
18	Bayesian Adaptive Methods with Pharmacogenomics to Treat Bladder Cancer	Co-I	VA Merit Award	10/1/07 - 9/30/12	\$20,000
19	*PRJ13GL: E5803 Correlatives	PI	NIH/NCI	07/07/07 - 5/30/08	\$25,000
20	*144-PR21: Task order no. 3 for correlative studies for clinical protocol (p7024): a phase ii trial of bevacizumab and erlotinib in patients with advanced biliary tumors.	PI	NIH/NCI	8/9/06 - 8/8/08	\$50,000
21	*133-JA91: E1503: Analysis of MDR Polymorphisms	PI	NIH/NCI	07/07/06 - 7/08/07	\$25,000
22	U19 CA113297: National Cooperative Drug Discovery Group for Cancer	Core C Co-Leader/Faculty Supervisor	NIH/NCI	06/21/05 - 04/30/10	\$79,566
23	*133-HF89: Phase I Study of the Oral Platinum Agent Satriplatin (GM-216) in Combination with Docetaxel in Treatment of Advanced Malignancies	Co-I	GPC Biotech	05/15/05 - 8/8/08	\$12,000
24	5 P30 CA014520-33: Lung Cancer Planning Grant for Translational Studies	Pilot project leader	NIH/NCI	04/01/04 - 03/31/06	\$75,000
25	*133-GF31: Pilot Study of Iressa and Faslodex in the Treatment of Post-Menopausal Women with Advanced Recurrent Non-Small Cell Lung Cancer.	Co-I	AstraZeneca	02/09/04 - 02/11/05	\$25,000
26	*UWM1302AVN-00: E1302: Evaluation of Cytochrome p450 polymorphism as a predictor of docetaxel response; analysis of the pharmacokinetics of docetaxel.	PI	NIH/NCI	08/06/04 - 06/02/11	\$32,000
27	5 P30CA014520-41: UW Comprehensive Cancer Center Support	Shared Resource Leader	NIH/NCI	04/25/03 - 03/31/16	\$1,001,000
28	1 U10CA180799-02 National Clinical Trials Network Research at the University of Wisconsin	Co-I	NIH/NCI	4/22/03 - 02/28/16	\$334,641
29	*133-ER19: Apoptosis Markers in Patients Receiving Arsenic Trioxide	Co-I	Cell Therapeutics	01/15/02 - 05/04/04	\$17,000
30	Preclinical Evaluation of Direct Detection for HIV.	PI	Robert Wood Draper Foundation	7/00 - 7/01	\$50,000
31	A Web Based Virtual Patient for the Oncology Pharmacotherapy Lab	PI	UW Madison Teaching Academy	8/00 - 8/01	\$2500

32	Direct Detection of Nucleic Acids	PI	Robert Wood Draper Foundation	7/99 -8/00	\$75,000
33	*1R21 PAR-97-006: Daily Perillyl Alcohol Therapy in Advanced Colorectal Cancer.	Co-I	NIH/NCI	1/99 - 12/01	\$35,000
34	Development of the Virtual Patient for the Oncology Pharmacotherapy Lab.	PI	UW Madison Teaching Academy	8/99 - 8/00	\$2500
35	NQO1 Model Development	PI	American Cancer Society	4/9 8- 4/99	\$10,000
36	5 U01CA062491-19: Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)	Co-I	NIH/NCI	02/27/98 - 02/28/14	\$401,115
37	NQO1 Gene Expression and Mutation Status to Predict MMC Chemosensitivity	PI	American College of Clinical Pharmacy	3/98 - 2/03	\$10,000
38	Detection of Topoisomerase Point Mutations and Gene Expression. Role: Principal Investigator	PI	Pharmacia-UpJohn	9/97 - 8/00	\$18,000

Peer-Reviewed Original Research in Professional, Scientific or Educational Journals - Trainees are underlined

1. **Kolesar JM**, Burris H, Kuhn JG. Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst 1995;87:1022-24.
2. **Kolesar JM**, Rizzo JD, Kuhn JG. Quantitative analysis of NQO1 gene expression by RT-PCR and CE-LIF. J Cap Elec 1995;2:287-90.
3. **Kolesar JM**, Burris H, Kuhn JG. Response to correspondence on: Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst 1995;87:1803-5.
4. **Kolesar JM**, Talbert RL, Kuhn JG. Elimination of NQO1 gene expression by vitamin E. J Onc Pharm Pr 1996;2:10-3.
5. Kinikar SA, **Kolesar JM**. Identification of a Potential Gemcitabine -Warfarin Drug Interaction. Pharmacotherapy 1999;19:1331-3.
6. **Kolesar JM**, Johnson C, Freeberg E, Berlin J, Schiller J. A potential 5FU-warfarin drug interaction. A consecutive case series. Pharmacotherapy 1999;19:1445-9.
7. **Kolesar JM**, Allen PA, Doran CM. Direct detection of HIV-1 RNA by CE-LIF. J Chrom B 1997;697:189-194.
8. Dhurander N, Isreal B, **Kolesar JM**, Atkinson R. Increased adiposity in animals due to human virus. International J of Obesity; 2000 24:989-996.
9. **Kolesar JM**, Miller JA, Dhurandar N, Atkinson R. Direct detection of AD-36 DNA. J Chrom B 2000;744:1-8.
10. Dhurandhar NV, Israel BA, **Kolesar JM**, Mayhew G, Cook ME and Atkinson RL. Transmissibility of adenovirus-induced adiposity in a chicken model. International Journal of Obesity 2001; 25, 990 – 1006.

11. **Kolesar JM**, Pritchard SC, Kerr KM, Nicolson MC, McLeod HL. Evaluation of NQO1 Gene Expression and Variant Allele in Human NSCLC Tumors and Matched Normal Lung Tissue. *Internat J Oncol* 5:1119-24, 2002.
12. **Kolesar JM**, Allen PG. NQOR Enhances Proliferation Inhibition by 4-Hydroxytamoxifen. *Anti-Cancer Research* 2002;22:1475-78.
13. Villalona-Calero, MA, **Kolesar JM**. MMC as a modulator of irinotecan anticancer activity. *Oncology* 2002;16:21-25.
14. Meadows SM, Mulkerin D, Berlin J, Bailey H, **Kolesar J**, Warren D, Thomas JP. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. *Int J Gastrointest Cancer* 32(2-3):125-8, 2002.
15. **Kolesar JM**, Duren E, Baranski BB. Retrospective Evaluation of Response to Epoetin Alfa in Patients with Hematologic Disorders, *JOPP* 10:1-6, 2004.
16. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, **Kolesar J**, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. *Clin Cancer Res* 10(22):7450-6, 2004.
17. Sweeney C, Liu G, Yiannoutsos C, **Kolesar J**, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. *Clin Cancer Res* 11(18):6625-33, 2005.
18. Dubey SD, Stephenson O, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, **Kolesar JM**. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. *J Thor Oncology* 2006, 1: 406-412.
19. Argiris A, Hensing T, Yelandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M. **Kolesar JM**. Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small-Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. *J Thorac Oncol*. 2006;1: 1-1-9.
20. **Kolesar JM**, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine((R)). *J Inorg Biochem*. 2008 Apr;102(4):693-8. Epub 2007 Oct 30.
21. Pomplun M, Johnson JJ, Johnston S, **Kolesar JM**. Stability of a heparin-free 50% ethanol lock solution for central venous catheters. *J Oncol Pharm Pract*. 2007 Mar;13(1):33-7.
22. Mulcahy M, Hochster H, Ryan T, Avram M, **Kolesar J**, Benson A. Docetaxel, oxaliplatin and 5-fluorouracil: A phase I, pharmacokinetic and pharmacogenomic study. *Ann Oncol*. 2008;17:96-96.
23. Loconte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, **Kolesar J**. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2008 Mar 6.
24. Attia S, **Kolesar J**, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. *Invest New Drugs* 2008 Aug;26(4):369-79.
25. Liu G, **Kolesar J**, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense

Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2008 May 1;14(9):2732-2739.

26. Mrozek E, **Kolesar J**, Young D, Allen J, Villalona-Calero M, Shapiro CL. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). *Ann Oncol.* 2008 Apr 11. [Epub ahead of print]
27. Argiris, A., Buchanan, A., Brockstein, B., **Kolesar, J.**, Ghebremichael, M., Pins, M., et al. (2009). Docetaxel and irinotecan in recurrent or metastatic head and neck cancer. *Cancer*, 115(19), 4504-4513.
28. Chang, J. E., Voorhees, P. M., **Kolesar, J. M.**, Ahuja, H. G., Sanchez, F. A., Rodriguez, G. A., et al. (2009). Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin oncology network study. *Hematological Oncology*, 27(1), 11-16.
29. **Kolesar, J.**, Huang, W., Eickhoff, J., Hahn, K., Alberti, D., Attia, S., et al. (2009). Evaluation of mRNA by Q-RT-PCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. *Cancer Chemother Pharmacol*, 64(1), 79-86.
30. Mulkerin, D., LoConte, N. K., Holen, K. D., Thomas, J. P., Alberti, D., Marnocha, R., **Kolesar J**, et al. (2009). A phase I study of an oral simulated FOLFOX with high dose capecitabine. *Investigational New Drugs*, 27(5), 461-468.
31. Schelman, W. R., Morgan-Meadows, S., Marnocha, R., Lee, F., Eickhoff, J., Huang, W., **Kolesar J**, et al. (2009). A phase I study of triapine (R) in combination with doxorubicin in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, 63(6), 1147-1156.
32. Traynor, A. M., Dubey, S., Eickhoff, J. C., **Kolesar, J. M.**, Schell, K., Huie, M. S., et al. (2009). Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin oncology network phase II study. *J Thorac Oncol*, 4(4), 522-6.
33. Mancl, E. E., **Kolesar, J. M.**, & Vermeulen, L. C. (2009). Clinical and economic value of screening for kras mutations as predictors of response to epidermal growth factor receptor inhibitors. *Am J Health Syst Pharm*, 66(23), 2105-12.
34. Traynor, A. M., Schiller, J. H., Stabile, L. P., **Kolesar, J. M.**, Eickhoff, J. C., Dacic, S., et al. (2009). Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. *Lung Cancer*, 64(1), 51-9.
35. Vermuelen, L. C., Puffer, E. B., Hallam, M., Sollinger, H. W., Hoke, R., & **Kolesar, J. M.** (2009). Stability of alemtuzumab for low-dose induction and test doses. *American Journal of Transplantation*, 9(3), 651-652.
36. Xu, Y., **Kolesar, J. M.**, Schaaf, L. J., Drengler, R., Duan, W., Otterson, G., et al. (2009). Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. *Cancer Chemotherapy and Pharmacology*, 63(6), 1073-1082.
37. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, **Kolesar JM**, Schiller JH. A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. *Invest New Drugs*. 2010 Feb;28(1):91-7.
38. Hamidovic A, Hahn K, **Kolesar J.** Clinical significance of ABCB1 genotyping in oncology .*J Oncol Pharm Pract.* 2010 Mar;16(1):39-44. Epub 2009 Apr 28.
39. Ikesue H, Vermeulen LC, Roke, R, **Kolesar JM.** Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. *Am J Health Syst Pharm.* 2010 Feb 1;67(3):223-6.

40. **Kolesar JM, Hoel R, Pomplun M, et al.** A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. *Cancer Prev Res (Phila)*. 2010 Dec;3(12):1565-70.
41. **Ikeda R, Vermeulen LC, Lau E, Jiang Z, Kavanaugh S, Yamada K, Kolesar J.** Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. *Oncology Letters* 2010 *Oncol Lett*. 2011 Jan;2(1):91-94. Epub 2010 Oct 19.
42. **Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar J.** Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. *Mol Med Rep*. 2010 Nov-Dec;3(6):1031-4
43. **Ikeda R, Vermeulen LC, Lau E, Jiang Z, Kolesar J.** Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. *Experimental and therapeutic medicine* 2010;1:853-57.
44. **Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD.** The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. *Cancer Chemother Pharmacol*. 2010 Oct;66(5):973-80.
45. **Lubner SJ, Mahoney MR, Kolesar J, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD.** Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. *J Clin Oncol*. 2010 Jul 20;28(21):3491-7.
46. **Eickhoff JC, Kyungmann Kim, Beach J, Kolesar JM, Gee JR.** A Bayesian adaptive design with biomarkers for targeted therapies. *Clin Trials*. 2010 Oct;7(5):546-56.
47. **Delgado DC, Hank JA, Kolesar J, Lorentzen DF, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang RK, Gadbar B, Desantes KD, London W, Seeger RC, Maris J, Sondel PM.** Genotypes of NK cell KIR receptors, their ligands, and Fc{gamma} Receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. *Cancer Res*. 2010 Dec 1;70(23):9554-61.
48. **Vanderloo JP, Pomplun ML, Vermeulen LC, Kolesar JM.** Stability of unused reconstituted bortezomib in original manufacturer vials. *J Oncol Pharm Pract*. 2011 Dec;17(4):400-2.
49. **Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanadam K, Yamada K, Kolesar J.** Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. *Int J Oncol*. 2011 Feb;38(2):513-9.
50. **Sylvester RK, Steen P, Tate JM, Mehta M, Petrich RJ, Berg A, Kolesar J.** Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. *Anticancer Drugs*. 2011 Jan;22(1):104-10.
51. **Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G.** Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. *Cancer Chemother Pharmacol*. 2011 Feb;67(2):393-400.
52. **Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G** Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate. *Clin Cancer Res*. 2011 Dec 15;17(24):7634-44.

53. Liu G, Chen YH, **Kolesar J**, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bublely GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. *Urol Oncol*. 2013 Feb;31(2):211-8.
54. Shin HC, Alani AW, Cho H, Bae Y, **Kolesar JM**, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. *Mol Pharm*. 2011 Aug 1;8(4):1257-65. Epub 2011 Jun 23.
55. **Kolesar JM**, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, Keller SM, Schiller JH. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. *Oncol Rep*. 2011 Jun;25(6):1765-72. doi: 10.3892/or.2011.1249. Epub 2011 Apr 6.
56. Ramalingam SS, Lee JW, Belani CP, Aisner SC, **Kolesar J**, Howe C, Velasco MR, Schiller JH. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). *J Clin Oncol*. 2011 May 1;29(13):1709-14. Epub 2011 Mar 21.
57. **Kolesar JM**, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. *Exp Ther Med*. 2011 Jan;2(1):119-123.
58. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanandam K, Yamada K, **Kolesar JM**. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. *Int J Oncol*. 2011 Feb;38(2):513-9
59. Sylvester RK, Steen P, Tate JM, Mehta M, Petrich RJ, Berg A, **Kolesar J**. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. *Anticancer Drugs*. 2011 Jan;22(1):104-10.
60. Vanderloo JP, Pomplun ML, Vermeulen LC, **Kolesar JM**. Stability of unused reconstituted bortezomib in original manufacturer vials. *J Oncol Pharm Pract*. 2011 Dec;17(4):400-2.
61. Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, **Kolesar J**, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. *Cancer Prev Res (Phila)*. 2012 Apr;5(4):621-30.
62. Shin HC, Cho H, Lai TC, Kozak KR, **Kolesar JM**, Kwon GS. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. *J Control Release*. 2012 Oct 10;163(1):93-9.
63. Sachidanandam K, Gayle AA, Robins HI, **Kolesar JM**. Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase. *J Oncol Pharm Pract*. 2012 Nov 15
64. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, **Kolesar JM**. Stability of infliximab in polyvinyl chloride bags. *Am J Health Syst Pharm*. 2012 Sep 1;69(17):1509-12
65. Schelman WR, Traynor AM, Holen KD, **Kolesar JM**, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. *Invest New Drugs*. 2013 Dec;31(6):1539-46.
66. **Kolesar JM**, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced

malignancies directly alters transcription of target genes. *Cancer Chemother Pharmacol*. 2013 Sep;72(3):661-7.

67. Evens AM, Carson KR, **Kolesar J**, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. *Ann Oncol*. 2013 Dec;24(12):3076-81.
68. Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, Gascoyne RD, **Kolesar J**, Kahl BS, Horning S. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). *J Hematol Oncol*. 2013 Jul 5;6:46. doi: 10.1186/1756-8722-6-46.
69. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, **Kolesar JM**, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. *J Clin Oncol*. 2013 Apr 10;31(11):1405-14.
70. Gee J, Bailey H, Kim K, **Kolesar J**, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1 α -hydroxyvitamin D2 in patients with clinically localized prostate cancer and high-grade pin. *Prostate*. 2013 Jun;73(9):970-8
71. Hammers H, **Kolesar J**, Stein MN, Eickhoff JC, Carmichael L, Johnston S, Perlman S, Jeraj R, Liu G. A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies. *J Clin Oncol*. 2013 Feb 20;31(6_suppl):434.
72. Hoang T, Campbell TC, Zhang C, Kim K, **Kolesar JM**, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. *Invest New Drugs*. 2014 Feb;32(1):195-9.
73. **Kolesar JM**, Eickhoff J, Vermeulen LC. Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? *Am J Health Syst Pharm*. 2014 Mar 15;71(6):507-10.
74. Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, **Kolesar JM**, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH. Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). *Eur J Cancer*. 2014 Jan;50(2):302-8.
75. Deming DA, Ninan J, Bailey HH, **Kolesar JM**, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. *Invest New Drugs*. 2014 Apr;32(2):323-9.
76. Schelman WR, Mohammed TA, Traynor AM, **Kolesar JM**, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. *Invest New Drugs*. 2014 Apr;32(2):295-302.
77. Wisinski KB, Ledesma WM, **Kolesar J**, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1 α ,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. *J Oncol Pharm Pract*. 2014 Jul 1. pii: 1078155214541572. [Epub ahead of print]

78. Bruce JY, **Kolesar JM**, Hammers H, Stein MN, Carmichael L, Eickhoff J, Johnston SA, Binger KA, Heideman JL, Perlman SB, Jeraj R, Liu G. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. *Cancer Chemother Pharmacol*. 2014 Mar;73(3):485-93.
79. Schwan WR, **Kolesar JM**, Kabir MS, Elder EJ Jr, Williams JB, Minerath R, Cook JM, Witzigmann CM, Monte A, Flaherty T. Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. *Antibiotics (Basel)*. 2015 Dec;4(4):617-626. Epub 2015 Nov 24.
80. Bruce JY, Scully PC, Carmichael LL, Eickhoff JC, Perlman SB, **Kolesar JM**, Heideman JL, Jeraj R, Liu G. Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. *Cancer Chemother Pharmacol*. 2015 Jul;76(1):187-95.
81. Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, **Kolesar JM**. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. *Am J Health Syst Pharm*. 2015 Jun 1;72(11):958-65.
82. LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, **Kolesar J**, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. *Invest New Drugs*. 2015 Feb;33(1):169-76.
83. **Kolesar JM**, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH. Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. *J Oncol Pharm Pract*. 2015 Apr;21(2):128-31.
84. Hanna NH, Dahlberg SE, **Kolesar JM**, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). *Cancer*. 2015 Jul 1;121(13):2253-61.
85. Bergsbaken J, Eickhoff J, Buss B, Mably M, **Kolesar J**. Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review. *J Oncol Pharm Pract*. 2016 Feb;22(1):105-13.
86. Sippy R, **Kolesar JM**, Darst BF, Engelman CD. Prioritization of family member sequencing for the detection of rare variants. *BMC Proceedings* 2016; 10 (S7):11.
87. Rastegar-Mojarad M, Ye J, **Kolesar JM**, Lin SM and Hebring SJ. Phenome-Wide Association Studies (PheWASs) Offer New Opportunities for Drug Repositioning. *Nature Biotechnology* 2015 Apr;33(4):342-5.
88. Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwalla M, Eickhoff J, Bell MC, **Kolesar JM**, Flynn C, Liu G. Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer. *Clin Cancer Res*. 2016 Jun 1;22(11):2659-67.
89. Gee JR, Saltzstein DR, Messing E, Kim K, **Kolesar J**, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of diindolymethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. *Eur J Cancer Prev*. 2016 Jul;25(4):312-20.
90. Kyriakopoulos CE, Heath EI, Eickhoff JC, **Kolesar J**, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. *Invest New Drugs*. 2016 Apr;34(2):225-30.

91. Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, **Kolesar JM**, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. *Invest New Drugs*. 2016 Apr;34(2):168-75.
92. Walko C, Kiel PJ, **Kolesar JM**. Precision medicine in oncology: New practice models and roles for oncology pharmacists *Am J Health Syst Pharm*. 2016 Dec 1;73(23):1935-1942.
93. Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, **Kolesar J**, Tevaarwerk AJ. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. *Invest New Drugs*. 2016 Nov 8. [Epub ahead of print]
94. Scarpelli M, Bruce JY, Carmichael L, Eickhoff J, **Kolesar J**, Perlman S, Jeraj R, Liu G. 18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. *Cancer Chemother Pharmacol*. 2016 Dec;78(6):1245-1252.
95. Jarrard D, Konety B, Huang W, Downs T, **Kolesar J**, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early-stage prostate cancer undergoing prostatectomy. *Am J Clin Exp Urol*. 2016 Sep 20;4(2):17-27.
96. Kyriakopoulos CE, Braden AM, **Kolesar JM**, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. *Invest New Drugs*. 2016 Dec 21. [Epub ahead of print]
97. Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, **Kolesar JM**, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. *Pediatr Blood Cancer*. 2016 Dec 30. [Epub ahead of print]
98. Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, **Kolesar JM**. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. *J Oncol Pharm Pract*. 2017 Jan 1:1078155217704989.
99. Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, **Kolesar JM**, Huse JT, Kramer K, Cheung NV, Dunkel IJ. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. *PLoS One*. 2017 Jun 5;12(6):e0178593.
100. Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, **Kolesar JM**, Kuhn JG, Sportelli P, Miskin HP, O'Connor OA. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. *Br J Haematol*. 2017 Apr;177(2):243-253.
101. Gee JR, Saltzstein DR, Kim K, **Kolesar J**, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. *Cancer Prev Res (Phila)*. 2017 May;10(5):298-307.
102. Burkard ME, Deming D, Parsons K, Schuh M, Leal T, Uboha N, Lang J, Thompson M, Warren R, Bauman J, Mably M, Laffin J, Paschal C, Lager A, Lee K, Matkowskyj K, Buehler D, Rehrauer W, **Kolesar J**. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. *JCO Precision Oncology*, Published online on ascopubs.org/journal/po on July 5, 2017.
103. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, **Kolesar JM**, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly

K, Santella RM, Albain KS, Ambrosone CB. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). *J Natl Cancer Inst.* 2018 Jan 13.

104. **Kolesar JM**, Liu GX. Low-Fat Abiraterone Food Effect Is of Little Consequence. *J Clin Oncol.* 2018 Mar 28.
105. Chauhan A, Arnold SM, **Kolesar J**, Thomas HE, Evers M, Anthony L. Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status. *Oncotarget.* 2018 Feb 22;9(18):14738-14740.
106. Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, **Kolesar J**, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, Bruce JY. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. *Cancer Chemother Pharmacol.* 2018 Aug;82(2):211-219.
107. Huang T, Engelmann BJ, Morgan RM, Absher KJ, **Kolesar JM**, Villano JL. EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib. *Cancer Chemother Pharmacol.* 2018 May;81(5):965-968.
108. **Kolesar JM**, Liu G. Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. *J Clin Oncol.* 2018 Sep 6.
109. Nichols D, Arnold S, Weiss H, Wu J, Durbin E, Miller R, **Kolesar J**. Pharmacogenomic potential in advanced cancer patients. *AJHP* 2019; 76:415-23.
110. Snell AA, Neupane KR, McCorkle JR, Fu X, Moonschi FH, Caudill EB, **Kolesar J**, Richards CI. Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery. *ACS Omega.* 2019 Jul 24;4(7):12657-12664.
111. **Kolesar JM**, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH. A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. *Cancer Prev Res (Phila).* 2019 Sep 4.
112. Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland F, **Kolesar JM**. Olaparib combined with an ATR or CHK1 inhibitor as a treatment strategy for acquired olaparib resistant BRCA1 mutant ovarian cancer cells. *Diagnostics* 2020;10:121.
113. Riggs, M. J., Huang, B., Chen, Q., Bocklage, T. J., Schuh, M. R., Poi, M., Villano, J. L., Cavnar, M. J., Arnold, S. M., Miller, R. W., Ueland, F. R., **Kolesar, J.** (2020). Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky. *Journal of Rural Health.* *J Rural Health.* 2020 Jul 6. doi: 10.1111/jrh.12492.
114. Liu S, Liu J, Xie Y, Zhai T, Hinderer EW, Stromberg AJ, Vanderford NL, **Kolesar JM**, Moseley HNB, Chen L, Liu C, Wang C. MEScan: a powerful statistical framework for Genome-Scale mutual exclusivity analysis of cancer mutations. *Bioinformatics.* 2020 Nov 9:btaa957.
115. Larson, K. L., Huang, B., Chen, Q., Tucker, T. C., Schuh, M., Arnold, S. M., **Kolesar, J.** (2020). EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. *PLoS ONE*, 15(8 August). http://https://api.elsevier.com/content/abstract/scopus_id/85089649168
116. Riggs MJ, Lin N, Wang C, Piecoro DW, Miller RW, Hampton OA, Rao M, Ueland FR, **Kolesar J**. DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. *PLOS One*, *PLOS One.* 2020 Dec 30;15(12):e0244558.
117. Bertino EM, Gentzler, R, Clifford S, **Kolesar JM**, Muzikansky A, Haura EB, Piotrowska Z, Cambridge DR, Stinchcombe TE, Hann C, Malhouta J, Villaruz LC, Paweletz C, Lau C, Sholl L, Takebe N, Moscow JA,

Shapiro G, Janne PA, Oxnard GR. Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). *CI Cancer Res*, 2020 Dec 29;clincanres.4084.2020.

118. Myint ZW, Momo HD, Otto DE, Yan D, Wang P, **Kolesar JM**. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020 Nov 2;3(11):e2025826.
119. Neupene KR, McCorkle JR, Kopper TJ, Lakes SP, Aryal SP, Addullah M, Snell AS, Gensel J, **Kolesar J**, Richards CI. Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization. *ACS Omega* 2021, 6, 5, 3847–3857.
120. Jacob A, Wu J, **Kolesar J**, Durbin E, Mathew A, Arnold S, Chauhan A. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. *Cancer Med*. 2021 Feb 22.
121. McDowell A Jr, Hill KS, McCorkle JR, Gorski J, Zhang Y, Salahudeen AA, Ueland F, **Kolesar JM**. Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. *Diagnostics (Basel)*. 2021 Feb 26;11(3):395.
122. Hill KS, McDowell A, McCorkle JR, Schuler E, Ellingson SR, Plattner R, **Kolesar JM**. KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer. *Cancers (Basel)*. 2021 Apr 14;13(8):1885.
123. Patel RA, Lin M, Harper M, Beck S, Dietrich CS, **Kolesar JM**, Arnold SA, Hahn J, Pandalai PK, Qasem SA, Kim J. Pediatric patient with peritoneal mesothelioma harboring ALK rearrangement. *Current Problems in Cancer: Case Reports* 2021;4:100074.
124. McCorkle JR, Gorski JW, Liu J, Riggs MB, McDowell AB, Lin N, Wang C, Ueland FR, **Kolesar JM**. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. *PLoS ONE* 16(8): e0254205. <https://doi.org/10.1371/journal.pone.0254205>
125. Forster D, Lin N, Levens J, Stone R, Berry S, Durbin E, Jennings CJ, DiPaola RS, **Kolesar JM**. Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center – An assessment of occupational infection risk. *Am J Inf Control* 2021; 49:1158-61.
126. Huang B, Chen Q, Allison D, El Khouli R, Peh KH, Mobley J, Anderson A, Durbin EB, Goodin D, Villano JL, Miller RW, Arnold SA, **Kolesar JM**. Molecular tumor board review and improved overall survival in non-small-cell lung cancer. *JCO Precis Oncol*. 2021 Sep 29;5:PO.21.00210.
127. Gorski JW, Zhang Z, McCorkle JR, DeJohn JM, Wang C, Miller RW, Gallion HH, Dietrich CS, Ueland FR, **Kolesar JM**. Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. *Biomedicines*. 2021 Aug 16;9(8):1021.
128. Hutchcraft ML, Lin N, Zhang S, Sears C, Zacholski K, Belcher EA, Durbin EB, Villano JL, Cavnar MJ, Arnold SM, Ueland FR, **Kolesar JM**. Real-World Evaluation of universal germline pharmacogenomic screening for patients with cancer. *Cancers (Basel)*. 2021 Sep 8;13(18):4524.
129. Chauhan A, Prieur A, **Kolesar J**, Arnold S, Payen L, Mahi Y, Vire B, Sands M, Evers BM, Joubert D, Anthony L. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors. *Cancers (Basel)*. 2022 Feb 9;14(4):863.
130. **Kolesar JM**, Gayheart T, Poston L, et al. Preliminary Research on a COVID-19 Test Strategy to Guide Quarantine Interval in University Students. *COVID* 2022; 2: 254-263.

131. Zhang Y, Hammonds A, Tran-Harding K, Schaberg KB, Nair RT, Wang C, Wu Y, Pandalai PK, **Kolesar J**, Kim J, Cavnar MJ. Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas. *J Surg Case Rep*. 2022 Mar 22;2022(3):rjac096.
132. Hutchcraft ML, Zhang S, Lin N, Gottschalk GL, Keck JW, Belcher EA, Sears C, Wang C, Liu K, Dietz LE, Pickarski JC, Wei S, Cardarelli R, DiPaola RS, **Kolesar JM**. Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients. *J Pers Med*. 2022 Aug 8;12(8):1297.
133. Miller RW, Hutchcraft ML, Weiss HL, Wu J, Wang C, Liu J, Jayswal R, Buchanan M, Anderson A, Allison DB, El Khouli RH, Patel RA, Villano JL, Arnold SA, **Kolesar JM**. Molecular Tumor Board Assisted Care in an Advanced Cancer Population: Results of a Phase 2 Clinical Trial. *JCO Precision Oncology* 2022 Sept 14; on-line first.
134. Myint ZW, **Kolesar JM**, McCorkle JR, Wu J, Ellis CS, Otto DE, Wang P. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer. *Med Sci Monit*. 2022 Oct 14;28:e938091.
135. Jeong JC, Hands I, **Kolesar JM**, Rao M, Davis B, Dobyns Y, Hurt-Mueller J, Levens J, Gregory J, Williams J, Witt L, Kim EM, Burton C, Elbiheary AA, Chang M, Durbin EB. Local data commons: the sleeping beauty in the community of data commons. *BMC Bioinformatics* 2022 Sep 23;23(Suppl 12):386.
136. Bhosale SS, Mandal A, Hou C, McCorkle JR, Schweer D, Hill KS, Subramanian V, **Kolesar JM**, Tsodikov OV, Rohr J. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers. *ChemMedChem* 2022 Nov 7;e202200368.
137. Myint ZW, **Kolesar JM**, McCorkle JR, Wu J, Ellis CS, Otto DE, Wang P. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone Refractory Prostate Cancer. *Med Sci Monit* 2022 Oct 14;29: e938091
138. Chen L, Burkard M, Wu J, **Kolesar JM**, Wang C Estimating the distribution of ratio of paired event times in phase II oncology trials. *Stat Med*. 2022 Dec 27.
139. Harvey BT, Fu X, Li L, Neupane KR, Anand N, **Kolesar JM**, Richards CI. Dendritic Cell Membrane-Derived Nanovesicles for Targeted T Cell Activation. *ACS Omega*. 2022 Dec 9;7(50):46222-46233.
140. Hoskins EL, Samorodnitsky E, Wing MR, Reeser JW, Hopkins JF, Murugesan K, Kuang Z, Vella R, Stein L, Risch Z, Yu L, Adebola S, Paruchuri A, Carpten J, Chahoud J, Edge S, **Kolesar J**, McCarter M, Nepple KG, Reilley M, Scaife C, Tripathi A, Single N, Huang RSP, Albacker LA, Roychowdhury S. Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations. *JCO Precis Oncol*. 2023 Jan;7:e2200300.
141. Schweer D, Anand N, Anderson A, McCorkle JR, Neupane K, Nail AN, Harvey B, Hill KS, Ueland F, Richards C, **Kolesar J**. Human macrophage-engineered vesicles for utilization in ovarian cancer treatment. *Front Oncol*. 2023 Jan 11;12:1042730.
142. Seong CS, Huang C, Boese AC, Hou Y, Koo J, Mouw JK, Rupji M, Joseph G, Johnston HR, Claussen H, Switchenko JM, Behera M, Churchman M, **Kolesar JM**, Arnold SM, Kerrigan K, Akerley W, Colman H, Johns MA, Arciero C, Zhou W, Marcus AI, Ramalingam SS, Fu H, Gilbert-Ross M. Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis. *bioRxiv*. 2023 Jan 27:2023.01.26.525772.
143. Ene A, Di J, Neltner JH, Pittman T, Arnold SM, **Kolesar JM**, Villano JL, Bachert SE, Allison DB. Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights. *Front Oncol*. 2023 Jan 31;13:1094274.

144. Myint ZW, St Clair WH, Strup SE, Yan D, Li N, Allison DB, McLouth LE, Ellis CS, Wang P, James AC, Hensley PJ, Otto DE, Arnold SM, DiPaola RS, **Kolesar JM**. A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer. *Cancers (Basel)*. 2023 Apr 27;15(9):2505
145. McDonald HG, Harper MM, Hill K, Gao A, Solomon AL, Bailey CJ, Lin M, Barry-Hundeyin M, Cavnar MJ, Mardini SH, Pandalai PJ, Patel RA, **Kolesar JM**, Rueckert JA, Hookey L, Ropeleski M, Merchant SJ, Kim J, Gao M. Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses. *Cancers (Basel)*. 2023 Jun 2;15(11):3036.
146. Rives TA, Pavlik H, Li N, Qasrawi L, Yan D, Pickarski J, Dietrich CS, Miller RW, Ueland FR, **Kolesar JM**. Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice. *Cancers (Basel)*. 2023 Jun 15;15(12):3192.
147. Neupane KR, Ramon GS, Harvey B, Chun B, Aryal SP, Masud AA, McCorkle JR, **Kolesar JM**, Kekenus-Huskey PM, Richards CI. Programming Cell-Derived Vesicles with Enhanced Immunomodulatory Properties. *Adv Healthc Mater*. 2023 Jun 28:e2301163.
148. Lozar T, Kim K, Havighurst TC, Wood GS, **Kolesar JM**, Bailey HH. Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design. *Eur J Cancer Prev*. 2023 Jul 3.
149. Chen Q, Huang B, Anderson AM, Durbin EB, Arnold SM, **Kolesar JM**. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in Kentucky and Appalachian Kentucky. *Front Oncol*. 2023 Aug 17;13:1193487.
150. Rosario SR, Dong B, Zhang Y, Hsiao HH, Isenhardt E, Wang J, Siegel EM, Monjazeb AM, Owen DH, Dey P, Tabung FK, Spakowicz DJ, Murphy WJ, Edge S, Yendamuri S, Ibrahimi S, **Kolesar JM**, McDonald PH, Vadehra D, Churchman M, Liu S, Kalinski P, Mukherjee S. Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers. *Int J Mol Sci*. 2023 Jun 29;24(13):10847.
151. Harbin LM, Lin N, Ueland FR, **Kolesar JM**. SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer. *Int J Mol Sci*. 2023 Sep 18;24(18):14212.
152. McDonald HG, Zaki OA, Wright MJ, Jayswal R, Weiss H, Nair RT, Ganesh H, Ellis S, **Kolesar JM**, Moss J, Barry-Hundeyin M, Pandalai PK, Kim J, Patel RA, Cavnar MJ. Phase I Safety and Feasibility Pilot of Hepatic Artery Infusion Chemotherapy in a Rural Catchment Area Using The Codman Vascular Catheter with The Medtronic SynchroMed II Pump for Intrahepatic Cancers. *Ann Surg Oncol*. 2024 Feb;31(2):1252-1263.
153. Hill KS, Schuler EE, Ellingson SR, **Kolesar JM**. Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells. *Sci Rep*. 2023 Dec 16;13(1):22383
154. Hutchcraft ML, Zhang S, Lin N, Pickarski JC, Belcher EA, Wei S, Bocklage T, Miller RW, Villano JL, Cavnar MJ, Kim J, Arnold SM, Ueland FR, **Kolesar JM**. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study. *JCO Precis Oncol*. 2024 Jan;8:e2300266
155. Brock P, Liyanarachchi S, Nieminen TT, Chan C, Kohlmann W, Stout LA, Yao S, La Greca A, Jensen KE, **Kolesar J**, Salhia B, Gulhati P, Hicks JK, Ringel MD. CHEK2 founder variants and thyroid cancer risk. *Thyroid*. 2024 Jan 27

Review Articles (Peer Reviewed) - Trainees underlined

1. **Kolesar JM**, Morris AK, Kuhn JG. Purine Nucleoside Analogues: Focus on Fludarabine. *J Onc Pharm Pr* 1996; 2:160-181.
2. **Kolesar JM**, Morris AK, Kuhn JG. Purine Nucleoside Analogues: Focus on Pentostatin. *J Onc Pharm Pr* 1996; 2:211-224.
3. Morris AK, **Kolesar JM**, Kuhn JG. Purine Nucleoside Analogues: Focus on Cladribine. *J Onc Pharm Pr* 1997; 3:94-109.
4. Dopp JM, **Kolesar JM**. Risk of Breast Cancer Associated with Hormone Replacement Therapy. *J Onc Phar Prac* 1999;3:109-116.
5. **Kolesar JM**. Taxotere in hepatic failure. *J Onc Phar Prac* 2000;6:43-49.
6. **Kolesar JM**. Novel approaches to anemia associated with cancer and chemotherapy. *American Journal of Health-System Pharmacy* 2002; 59(Suppl S):S8-S11.
7. Palmer M, Geurink J, Hahn K, **Kolesar JM**. Clinical pharmacology and determinates of response to Gefitinib in non-small cell lung cancer. *JOPP* 2004; 10:169-75.
8. **Kolesar, J**. Clinical Implications of BRCA1 and BRCA2. *The Female Patient* 29:51-57, 2004.
9. Sullivan M, Hahn K, **Kolesar JM**. Azacitidine: a novel agent for myelodysplastic syndromes. *Am J Health Syst Pharm* 62(15):1567-73, 2005.
10. Wilhelm L, **Kolesar JM**. Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm* 62(13):1365-9, 2005.
11. **Kolesar JM**. Bevacizumab: improved survival at what cost? *Am J Health Syst Pharm* 62(10):1017, 2005.
12. Hahn KK, Wolff JJ, **Kolesar JM**. Pharmacogenetics and irinotecan therapy. *Am J Health Syst Pharm*. Nov 15 2006;63(22):2211-2217.
13. Kabe KL, **Kolesar JM**. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. *Am J Health Syst Pharm*. Mar 15 2006;63(6):527-533.
14. Utecht KN, Hiles JJ, **Kolesar J**. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. *Am J Health Syst Pharm*. Dec 1 2006;63(23):2340-2348.
15. Fagan SC, Touchette D, Smith JA, **Kolesar J**, et al. The state of science and research in clinical pharmacy. *Pharmacotherapy*. Jul 2006;26(7):1027-1040.
16. **Kolesar JM**. Assessing therapeutically developed assays. *Manag Care*. 2008 Jul;17(7 Suppl 7):9-12; discussion 17-8.
17. Utecht KN, **Kolesar J**. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. *Am J Health Syst Pharm*. 2008 Jul 1;65(13):1221-31.
18. Hallam MJ, **Kolesar JM**. Hydroxyurea induced acute elevations in liver function tests. *J Oncol Pharm Pract*. 2008 Mar;14(1):61-3.
19. Hiles JJ, **Kolesar JM**. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. *Am J Health Syst Pharm*. 2008 Jan 15;65(2):123-31.
20. Dobbe E, Gurney K, Kiekow S, Lafferty JS, **Kolesar JM**. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. *Am J Health Syst Pharm*. 2008 Jan 1;65(1):23-8.

21. Gaston C, **Kolesar JM**. Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer. *Clinical Advances in Hematology and Oncology* 2008; 6:1-9.
22. Thompson A, **Kolesar J**. Breast Cancer Chemoprevention: Tamoxifen, Raloxifene or Neither? *Am J Health Syst Pharm* 2008 Dec 1;65(23):2221-2228.
23. Dennie TV and **Kolesar JM**. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory indolent B-cell non-hodgkin lymphoma. *Clinical Therapeutics* 2009; 31:2290-2311.
24. Tevaarwerk A and **Kolesar JM**. Lapatinib: A novel small molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor 2 tyrosine kinases used in the treatment of breast cancer. *Clinical Therapeutics* 2009;31:2332-2348.
25. Bonkowski J, Vermeulen LC, **Kolesar JM**. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. *J Oncol Pharm Pract*. 2010 Dec;16(4):223-32.
26. Kavanaugh SM, White LA, **Kolesar JM**. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. *Am J Health Syst Pharm*. 2010 May 15;67(10):793-7.
27. Pearson R, **Kolesar JM**. Targeted therapy for NSCLC: ALK inhibition. *J Oncol Pharm Pract*. 2012 Jun;18(2):271-4.
28. Simonsen KA, **Kolesar JM**. Lenalidomide-induced elevated bilirubin. *J Oncol Pharm Pract*. 2012 Dec;18(4):402-5.
29. Richardson PG, Eng C, **Kolesar J**, Hideshima T, Anderson KC. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. *Expert Opin Drug Metab Toxicol*. 2012 May;8(5):623-33.
30. Zhang Y, Simonsen K, **Kolesar JM**. Exemestane for primary prevention of breast cancer in postmenopausal women. *Am J Health Syst Pharm*. 2012 Aug 15;69(16):1384-8.
31. Gorden KJ, Mesbah P, **Kolesar JM**. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. *J Oncol Pharm Pract*. 2012 Jun;18(2):245-9.
32. Banaszynski M, **Kolesar JM**. Vemurafenib and ipilimumab: new agents for metastatic melanoma. *Am J Health Syst Pharm*. 2013 Jul 15;70(14):1205-10.
33. **Kolesar JM**, Vermeulen L. Assays for biological agents. *Am J Health Syst Pharm*. 2013 Jul 1;70(13):1101.
34. Poggi L, **Kolesar JM**. Vismodegib for the treatment of basal cell skin cancer. *Am J Health Syst Pharm*. 2013 Jun 15;70(12):1033-8.
35. Timm A, **Kolesar JM**. Crizotinib for the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm*. 2013 Jun 1;70(11):943-7.
36. Simonsen K, **Kolesar J**. New treatment options for castration-resistant prostate cancer. *Am J Health Syst Pharm*. 2013 May 15;70(10):856-65.
37. Ton GN, Banaszynski ME, **Kolesar JM**. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. *Am J Health Syst Pharm*. 2013 May 15;70(10):849-55.

38. Engle JA, **Kolesar JM**. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. *Am J Health Syst Pharm*. 2014 Nov 15;71(22):1933-8.
39. Fermiano M, Bergsbaken J, **Kolesar JM**. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. *Am J Health Syst Pharm*. 2014 May 15;71(10):793-8.
40. Piccolo J, **Kolesar JM**. Prevention and treatment of chemotherapy-induced peripheral neuropathy. *Am J Health Syst Pharm*. 2014 Jan 1;71(1):19-25.
41. Croegaert K, **Kolesar JM**. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm*. 2015 Sep 1;72(17):1456-62.
42. Engle JA, **Kolesar JM**. Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. *Am J Health Syst Pharm*. 2015 May 1;72(9):686-7.
43. Ivashko IN, **Kolesar JM**. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. *Am J Health Syst Pharm*. 2016 Feb 15;73(4):193-201.
44. Kujak C, **Kolesar JM**. Treatment of chronic myelogenous leukemia. *Am J Health Syst Pharm*. 2016 Feb 1;73(3):113-20.
45. Munroe M, **Kolesar J**. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. *Am J Health Syst Pharm*. 2016 Jul 15;73(14):1037-41.
46. Koth SM, **Kolesar J**. New options and controversies in the management of chemotherapy-induced nausea and vomiting. *Am J Health Syst Pharm*. 2017 Jun 1;74(11):812-819.
47. McGinty L, **Kolesar J**. Dinutuximab for maintenance therapy in pediatric neuroblastoma. *Am J Health Syst Pharm*. 2017 Apr 15;74(8):563-567.
48. Vermeulen LC, **Kolesar J**, Crismon ML, Flynn AJ, Stevenson JG, Almeter PJ, Heath WM, Short GT, Enright SM, Ploetz P, Swarthout MD, Zellmer WA, Saenz R, Devereaux DS, Zilz DA, Hoffman JM, Evans WE, Knoer SJ, Ray MD. ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems *Am J Health Syst Pharm*. 2018 Jan 15;75(2):23-54.
49. AMCP Partnership Forum: Managing Care in the Wave of Precision Medicine. *J Manag Care Spec Pharm*. 2018 May 23:1-6. doi: 10.18553/jmcp.2018.18071. [Epub ahead of print]
50. Burgess BT, **Kolesar JM** Defective DNA repair in hereditary ovarian cancers: Implications for therapy. *Am J Health Syst Pharm*. 2018 Nov 1;75(21):1697-1707.
51. Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, **Kolesar J**, Rao M. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. *J Clin Med*. 2019 Mar 18;8(3).
52. Raiker R, Chauhan A, Hasanein H, Burkeen G, Horn M, Veedu J, Vela C, Arnold S, **Kolesar J**, Anthony L, Evers BM, Cavnar M. Biliary tract large cell neuroendocrine carcinoma: current evidence. *Orphanet J Rare Dis*. 2019 Nov 21;14(1):266.
53. Roubal K, Myint ZW, **Kolesar JM** Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. *Am J Health Syst Pharm*. 2020 Feb 19;77(5):346-351.
54. Gorski JW, Ueland FR, **Kolesar JM**. CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. *Diagnostics (Basel)* 2020 May 5;10(5):279.

55. Jose A, Shenoy GG, Sunil Rodrigues G, Kumar NAN, Munisamy M, Thomas L, **Kolesar J**, Rai G, Rao PPN, Rao M Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy. *Cancers (Basel)*. 2020 Jul 31;12(8):2121.
56. Baburaj, G., Damerla, R. R., Udupa, K. S., Parida, P., Munisamy, M., **Kolesar, J.**, Rao, M. (2020). Liquid biopsy approaches for pleural effusion in lung cancer patients. *Molecular Biology Reports* 2020;10: 8179-8187.
57. Burkeen, G., Chauhan, A., Agrawal, R., Raiker, R., **Kolesar, J.**, Anthony, L. B., Evers, B. Mark, Arnold, S. M. (2020). Gynecologic large cell neuroendocrine carcinoma: A review (vol. 12). *Rare Tumors*. http://https://api.elsevier.com/content/abstract/scopus_id/85094659865
58. Schweer D, McCorkle JR, Rohr J, Tsodikov OV, Ueland F, **Kolesar J**. Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer. *Biomedicines*. 2021 Jan 12;9(1):70.
59. Hutchcraft ML, Gallion HH, **Kolesar JM**. MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. *Diagnostics (Basel)*. 2021 Jan 6;11(1):84.
60. Bissell BD, Johnston JP, Smith RR, Newsome AS, Thompson Bastin ML, Abdul-Mutakabbir J, Barlow A, Barlow B, Berger K, Crow JR, Dixit D, Jacobi J, Karaoui LR, Kiser TH, **Kolesar J**, Koontz SE, Mattingly TJ, Mitchell C, Nilges A, Rech MA, Heavner MS. *Am J Health Syst Pharm*. Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. 2021 Jul 7:zxab275. doi: 10.1093/ajhp/zxab275. Online ahead of print.
61. Larson KL. Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, Arnold SM, **Kolesar JM**. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review. *JCO Precision Oncology*. 2021 5;1122-1132.
62. **Kolesar JM**, Vermeulen LC. Precision medicine: Opportunities for health-system pharmacists. *Am J Health Syst Pharm*. 2021 May 24;78(11):999-1003.
63. Bissell BD, Johnston JP, Smith RR, Newsome AS, Thompson Bastin ML, Abdul-Mutakabbir J, Barlow A, Barlow B, Berger K, Crow JR, Dixit D, Jacobi J, Karaoui LR, Kiser TH, **Kolesar J**, Koontz SE, Mattingly TJ 2nd, Mitchell C, Nilges A, Rech MA, Heavner MS. Gender Inequity and Sexual Harassment in the Pharmacy Profession: Evidence and Call to Action Executive Summary. *J Am Coll Clin Pharm*. 2021 Nov;4(11):1375-1378.
64. Munisamy M, Mukherjee N, Thomas L, Pham AT, Shakeri A, Zhao Y, **Kolesar J**, Rao PPN, Rangnekar VM, Rao M. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions. *Am J Cancer Res*. 2021 Dec 15;11(12):5762-5781.
65. **Kolesar J**, Peh S, Thomas L, Baburaj G, Mukherjee N, Kantamneni R, Lewis S, Pai A, Udupa KS, Kumar An N, Rangnekar VM, Rao M. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. *Mol Cancer*. 2022 Feb 24;21(1):61.
66. **Kolesar JM**, Seeberger PH. Editorial: Anticancer Potential of Artemisia annua. *Front Oncol*. 2022 Feb 24;12:8534
67. Schweer D, McAtee A, Neupane K, Richards C, Ueland F, **Kolesar J**. Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy. *Cancers (Basel)*. 2022 Apr 29;14(9):2220.
68. Harbin LM, Gallion HH, Allison DB, **Kolesar JM**. Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy. *Diagnostics (Basel)*. 2022 Mar 29;12(4):842.
69. Anand N, Peh KH, **Kolesar JM**. Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. *Int J Mol Sci*. 2023 Feb 2;24(3):2858.

70. **Kolesar JM**, Arnold SM, Ueland FR, Evers BM. Bridging the Biomarker Chasm With Interprofessional Molecular Tumor Boards. *JCO Oncol Pract*. 2023 Jun 19:OP2300215.
71. Seligson ND, **Kolesar JM**, Alam B, Baker L, Lamba JK, Fridley BL, Salahudeen AA, Hertz DL, Hicks JK. Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. *Pharmacogenomics*. 2023 Aug;24(13):731-738

Book Editorships

1. Chisholm-Burns M, Wells B, Schwinghammer T, Malone, P, **Kolesar J**, Rotschaefer J, DiPiro J., eds. *Pharmacotherapy principles & practice*. New York: McGraw Hill; 2007.
2. Humma, L. M., Ellingrod, V. L. and **Kolesar, J. M.**, *Lexi-Comp's Pharmacogenomics Handbook*, Hudson, Ohio: Lexi-Comp, 1st ed 2006, 2nd ed 2008.
3. Humma, L. M., Ellingrod, V. L. and **Kolesar, J. M.**, *Lexi-Comp's Pharmacogenomics Handbook*, Hudson, Ohio: Lexi-Comp, 2006.
4. Chisholm-Burns M, Wells B, Schwinghammer T, Malone, P, **Kolesar J**, DiPiro J., eds. *Pharmacotherapy principles & practice*. 2nd ed New York: McGraw Hill; 2010.
5. **Kolesar JM** and Vermeulen L. eds. *2012-2013 Top 300 Pharmacy Drug Cards*. New York: McGraw Hill; 1st edition, 2012.
6. Chisholm-Burns M, Wells B, Schwinghammer T, Malone, P, **Kolesar J**, DiPiro J., eds. *Pharmacotherapy principles & practice*. 3rd ed New York: McGraw Hill; 2013
7. **Kolesar JM** and Vermeulen L. eds. *2015-2016 Top 100 NonPrescription Drug Cards*. New York: McGraw Hill; 1st edition, 2014
8. **Kolesar JM** and Vermeulen L. eds. *2014-2015 Top 300 Pharmacy Drug Cards*. New York: McGraw Hill; 2nd edition, 2014
9. Chisholm-Burns M, Wells B, Schwinghammer T, Malone, P, **Kolesar J**, DiPiro J., eds. *Pharmacotherapy principles & practice*. 4th ed New York: McGraw Hill; 2016
10. **Kolesar JM** and Vermeulen L. eds. *2016-2017 Top 300 Pharmacy Drug Cards*. New York: McGraw Hill; 3rd edition, 2016.
11. **Kolesar, J.**, Vermeulen, L. C. In *Kolesar and Vermeulen (Ed.)*, *2018-2019 Top 200 Drug Cards*. (1st ed., pp. 400). New York, New York: McGraw Hill, 2018
12. **Kolesar JM** and Vermeulen L. eds. *2018-2019 Top 300 Pharmacy Drug Cards*. New York: McGraw Hill; 4th edition, 2018.
13. **Kolesar JM** and Vermeulen L. eds. *2018-2019 Top 100 NonPrescription Drug Cards*. New York: McGraw Hill; 2nd edition, 2018
14. Chisholm-Burns M, Malone P, **Kolesar J**, Bookstaver, B, Lee K, Schwinghammer T., eds. *Pharmacotherapy principles & practice*. 5th ed New York: McGraw Hill; 2019
15. **Kolesar JM** and Vermeulen L. eds. *2020-2021 Top 300 Pharmacy Drug Cards*. New York: McGraw Hill; 5th edition, 2019

16. **Kolesar JM** and Vermeulen L. eds. 2020-2021 Top 100 NonPrescription Drug Cards. New York: McGraw Hill; 3rd edition, 2020
17. **Kolesar JM** and Vermeulen L. eds. 2022-2023 Top 300 Pharmacy Drug Cards. New York: McGraw Hill; 6th edition, 2021.
18. Chisholm-Burns M, Malone P, **Kolesar J**, Bookstaver, B, Lee K, Schwinghammer T., eds. Pharmacotherapy principles & practice. 6th ed New York: McGraw Hill; 2021
19. **Kolesar, J.**, Vermeulen, L. C. In Kolesar and Vermeulen (Ed.), 2020-2021 Top 200 Drug Cards. (2nd ed., pp. 400). New York, New York: McGraw Hill; 2021
20. **Kolesar, J.**, Vermeulen, L. C. In Kolesar and Vermeulen (Ed.), 2022-2023 Top 200 Drug Cards. (3rd ed., pp. 400). New York, New York: McGraw Hill, 2022.

Book Chapters (Peer Reviewed)

1. Goldspiel B, **Kolesar J**. Prostate Cancer. In: Pharmacotherapy: A Pathophysiologic Approach, 4th Edition, DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG and Posey LM (eds), Appleton-Lange, Inc., Stamford, CT 1999
2. **Kolesar J**, Kuhn J. Quantitative analysis of gene expression by RT-PCR and CE-LIF. In: Gene Quantification 1st ed., Ferre. 1996
3. **Kolesar JM**. Quantitation of Viral Load. Clinical and Forensic Applications of Capillary Electrophoresis, 1st ed., Petersen and Mohammad. Humana Press; 2000
4. Knoell DL, **Kolesar JM**. Gene Therapy In: Encyclopedia of Clinical Pharmacy, 1st Edition, DiPiro JT, (eds), McGraw Hill, Inc, 367-78, 2002
5. **Kolesar J**. Prostate Cancer. In: Pharmacotherapy: A Pathophysiologic Approach, 5th Edition, DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG and Posey LM (eds), Appleton-Lange, Inc., Stamford, CT 2002
6. **Kolesar JM**: Somatic Mutations in Oncology, in: Johnson JA, Ellingrod V, Kroetz D, Kao G, (eds), Pharmacogenomics: Applications to Patient Care, 1st Ed, American College of Clinical Pharmacy, Kansas, MO. 2003
7. **Kolesar JM**. Pharmacogenetic counseling. in: Figg WD, McLeod HL (eds), Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics, Humana Press, Totowa, 2004.
8. **Kolesar JM**. Prostate Cancer. In Pharmacotherapy. A Pathophysiologic Approach 6th edition. The McGraw-Hill Co. New York 2004.
9. Hoffman JA, **Kolesar JM**. Anemia. In: Tisdale JE, Miller DA, eds. Drug Induced Diseases: Prevention, Detection and Management. Bethesda, MD: American Society of Health System Pharmacists 2005.
10. **Kolesar JM**: Somatic Mutations in Oncology, in: Johnson JA, Ellingrod V, Kroetz D, Kao G, (eds), Pharmacogenomics: Applications to Patient Care, 2nd Ed, American College of Clinical Pharmacy, Kansas, MO. 2006
11. **Kolesar JM**. Prostate cancer. In: Chisholm-Burns M, Wells B, Schwinghammer T, et al., eds. Pharmacotherapy principles & practice. New York: McGraw Hill; 2007:1357-1370.

12. **Kolesar JM:** Somatic Mutations in Oncology, in: Johnson JA, Ellingrod V, Kroetz D, Kao G, (eds), Pharmacogenomics: Applications to Patient Care, 3rd Ed, American College of Clinical Pharmacy, Kansas, MO. 2009
13. McKibben T and **Kolesar JM.** Prostate cancer. In: Chisholm-Burns M, Wells B, Schwinghammer T, Malone, P, Kolesar J, DiPiro J., eds. Pharmacotherapy principles & practice. New York: McGraw Hill; 2nd edition. 2010
14. Leal T and **Kolesar JM.** Pharmacokinetics and Pharmacodynamic Monitoring. When is it Needed? Fundamentals of Oncology Clinical Trials: The Art and Science Behind Successful Clinical Trials 1st Ed. 2010
15. Norris L and **Kolesar JM.** Prostate cancer. In: DiPiro, J, Talbert, R, Yee G, et al., eds. Pharmacotherapy A Pathophysiologic Approach. New York: McGraw Hill; 8th edition. 2010
16. Sachidanandam K, **Kolesar J.** Clinical Pharmacogenetics. In: Figg WD, Rudek M (eds), Handbook Of Anticancer Pharmacokinetics And Pharmacodynamics, Humana Press, Totowa, 2013
17. Norris L and **Kolesar JM.** Prostate cancer. In: DiPiro, J, Talbert, R, Yee G, et al., eds. Pharmacotherapy A Pathophysiologic Approach. New York: McGraw Hill; 9th edition, 2014
18. **Kolesar J.** Clinical Pharmacology. In: American Society of Clinical Oncology-SEP. ASCO. Alexandria, VA 7th ed., 2020.

Active Therapeutic Clinical Trials as Principal Investigator of Major Role

1. **NCT05391126:** GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing versus Usual Care. Opened to accrual September 1, 2022
Role: PI of grant, trial based on preliminary data from my lab
Targeted Enrollment: 178
2. **NCT05254795:** PRiMAL- Pragmatic Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care. Opened to accrual April 14, 2022
Role: PI
Targeted Enrollment: 1000
3. **NCT04805333:** Phase 1 Dose Escalation of ArtemiCoffee. Opened to accrual June 9, 2021
Role: PI
Targeted Enrollment: 12
4. **NCT04903119:** Nilotinib plus Dabrafenib/Trametenib. Opened to accrual May 26, 2021.
Role: MPI
Targeted Enrollment: 15
5. **NCT04608409:** Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer. Opened to accrual October 29, 2020.
Role: Co-I, trial based on preliminary data from my lab
Targeted Enrollment: 15
6. **NCT04234568:** Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors. Opened to accrual January 21, 2020
Role: Co-I, trial based on preliminary data from my lab
Targeted Enrollment: 29

Completed Therapeutic Clinical Trials as Principal Investigator of Major Role

1. **NCT01935960.** Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers. Completed accrual October 2016.
Role: PI
Enrollment: 40
2. **NCT01336387** Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers. Completed accrual October 2012.
Role: PI
Enrollment: 50

PROFESSIONAL SERVICE

Current Memberships in Professional Organizations

American Association for Cancer Research (AACR)
 American Association of Colleges of Pharmacy (AACP)
 American College of Clinical Pharmacy (ACCP)
 American Society of Clinical Oncology (ASCO)
 International Society of Oncology Pharmacy Practice (ISOPP)

Leadership Positions Held

American Association of Colleges of Pharmacy

Delegate	1999
Alternate delegate	1998

American College of Clinical Pharmacy

Member, Presidential Task Force on DEIA	2023-present
Member, Nominations Committee	2021- 2023
Chair- Presidential Task Force on Advancing Women in Pharmacy Leadership	2019 - 2020
President-Elect, President and Immediate Past President	2016 - 2019
Research Institute, Board of Trustees	2012 - 2014
Board of Regents	2003 - 2006
Chair-Elect, Chair, Hematology Oncology PRN	2000 - 2002
Chair, Research Committee	1999 - 2000

Eastern Cooperative Oncology Group (ECOG)-ACRIN

Member, Lab Scientific Review Committee	2005 - 2020
Co-Chair, Lung Biology Subcommittee	2001 - 2017
Member, Developmental Therapeutics Core Committee	1998 - 2017
Member, Thoracic Core Committee	1998 - 2017

International Society of Oncology Pharmacy Practice

Chair, Membership Committee	2012 - 2014
Treasurer	2010 - 2012
Chair, Program Committee	2004

Oncology Research Information Exchange Network

Vice Chair, ORIEN Executive Committee	2022-2023
Chair, ORIEN Executive Committee	2023-2024
Vice Chair, ORIEN Steering Committee	2024-present
Co-Chair DEIA Research Interest Group	2024-present

National Cancer Institute

Member, Investigational Drug Steering Committee	2018 - present
Member, Cancer Prevention and Control Central IRB.	2014 - present
Translational Scientist PTMA# 100034: Cancer Therapy and Evaluation Program	2014 - present

Member, Investigational Drug Steering Committee Pharmacology Task Force	2012 - present
Member, National Cancer Institute Central Institutional Review Board (NCI CIRB)	2004 - 2009
Chair, NCI-CIRB Serious Adverse Events Sub-Committee	2004 - 2008

GRANT AND AWARD PEER REVIEWS

American Association of Colleges of Pharmacy

Paul A Dawson, Biotechnology Award	2003, 2006
New Investigators Program	2003
Innovations in Teaching Applications	2002

American College of Clinical Pharmacy

Member, Nominations Committee	2021 - present
Member, Paul Parker Medal Selection Committee	2020 - present
Abstract Reviewer	1997 - present

Cancer Prevention and Research Institute of Texas

Scientist reviewer	2019 - present
--------------------	----------------

Department of Defense

Scientist reviewer, Ovarian Cancer Research Program	2019 - present
Scientist reviewer, Lung Cancer Research Program	2013 - present

National Cancer Institute/National Institute of Health

Reviewer, NIH Director's New Innovator Award Program (DP2)	2021-2024
Reviewer, NIH/NIDCR, Clinical Trials Mechanism	2019 - 2024
Chair, NIH Special Emphasis Panel, Fellowship: Oncological Sciences	2016 - 2017
Reviewer, NIH Director's Early Independence Award Application	2011
Reviewer, NIH Special Emphasis Panel, Fellowship: Oncological Sciences	2009 - 2015

Patient Centered Outcomes Research Institute

Reviewer, Assessment of Prevention, Diagnosis and Treatment Options	2022
---	------

JOURNAL EDITORIAL BOARD MEMBERSHIP

AI in Cancer	2023-present
JCO Precision Oncology	2022-present
Cancer Chemotherapy and Pharmacology	2014 - present
Journal of Clinical Oncology	2011 - 2012
American Journal of Health System Pharmacy	2000 - 2003, 2008 - 2012
Journal of Oncology Pharmacy Practice	1997 - 2015

ACADEMIC PROGRAMS

American College of Clinical Pharmacy

Course Director: Oncology Genomics Certificate Program,	2021 - present
Faculty: FIT Research Training Program	2007, 19 - 2021

American Society of Health System Pharmacists

Faculty: Oncology Pharmacy Practice Specialty Examination Review Courses	1999 - 2010
--	-------------

University of Kentucky- Didactic and Experiential Courses Entry Level Pharm.D. Program

Coordinator: Deans Honor Course in Interprofessional Education	2017 - 2021
Participant: Integrated Drugs and Diseases 4: Oncology	2016 - present
Participant: Research & EBM in Pharmacy Practice	2016 - present
Participant: Specialty Pharmacy Practice Clerkships	2016 - present

UW-Madison Didactic and Experiential Courses Entry Level Pharm.D. Program

Coordinator:	Oncology Biomarkers	2015 - 2016
Coordinator:	Pharmaceutical Biotechnology and Pharmacogenomics	2002 - 2016
Coordinator:	Specialty Pharmacy Practice Clerkships	2000 - 2003
Participant:	Infectious Disease Pharmacotherapy IV	1999 - 2016
Participant:	Physicians Assistants Therapeutics	1998 - 2016
Instructor:	Independent Study Students	1998 - 2016
Preceptor:	Specialty Ambulatory Pharmaceutical Care Clerkships,	1997 - 2000
Participant:	Specialty Pharmacy Practice Clerkships	1996 - 2016
Coordinator:	Oncology/Hematology Pharmacotherapy IV	1996 - 2016
Participant:	Specialty Pharmacy Practice Clerkships	1996 - 2016
Participant:	Specialty Pharmacy Practice Clerkships	1996 - 2016

UW-Madison Nontraditional Pharm.D. Program (Program Termination in 2007)

Participant:	Immunology Pharmacotherapy	2000 - 2007
Participant:	Infectious Disease Pharmacotherapy	1999 - 2007
Coordinator:	Immunology Pharmacotherapy	1998 - 2000
Coordinator:	Oncology/Hematology Pharmacotherapy	1998 - 2007

UW-Madison Post-BS Pharm.D. Program (Program Termination May 2000)

Preceptor:	Ambulatory Pharmaceutical Care Clerkships	1997 - 2000
Coordinator:	Immunology Pharmacotherapy	1996 - 2000
Coordinator:	Clinical Medicine- Immunology	1996 -2000
Coordinator:	Conference of Research Workers	1996 - 2000
Participant:	Oncology/Hematology Pharmacotherapy	1996 - 2000
Preceptor:	Advanced Ambulatory Pharmaceutical Care Clerkships- Oncology	1998 - 2000
Instructor:	Independent Study students	1996 - 2000
Advisor:	Post-BS Pharm.D. students	1996 - 2000

ACADEMIC SERVICE CONTRIBUTIONS

University of Kentucky (University-wide)

Member, Obstetrics and Gynecology Department Chair Search	2023
Research Resumption Committee (COVID-19)	2020 - present
START committee	2020 - present
Chair, Academic Area Advisory Committee for Health Care Clinical Sciences	2019 - 2020
Member, Academic Area Advisory Committee for Health Care Clinical Sciences	2018 - 2020

University of Kentucky, College of Pharmacy

Strategic Planning Committee	2021 - present
Member, Promotion and Tenure Committee	2018 - present
Chair, Promotion and Tenure Committee	2022 - 2023

University of Kentucky, Markey Cancer Center

Shared Resources Advisory Committee, Markey Cancer	2020 - present
Cancer Research Informatics Scientific Advisory Committee	2018 - present
Co-Chair, Immunology Translational Working Group	2018 - present
Co-Chair, Experimental Therapeutic CCART	2016 - present
Member, Directors Council	2016 - 2023
Member, Membership Committee	2016 - present

University of Wisconsin (University-wide)

Member, Conflict of Interest Committee	2003 - 2007
Member, Emergency Salary Support for Senior Principal Investigators	2002 - 2016
Member, Academic Staff Indefinite Appointment Committee	2002 - 2007
Chair, Ruth S. Dickie Scholarship Competition	2002 - 2005
Member, Pharmacy School Dean Search Committee	2002 - 2003

Reviewer, Teaching and Learning with Technology Grant Applications	2002 - 2003
Member, Biological/Medical Sciences Area Review Committee	2001 - 2007
Member, Search Committee for Assistant Director of Business Development	2001

University of Wisconsin Carbone Comprehensive Cancer Center

Member, TSB Advisory committee	2011 - 2016
Chair, Drug interaction task force	2011 - 2016
Chair, Translational genetics working group	2010 - 2016
K12 Oncology Advisory Committee	2003 - 2016
Member, Thoracic Oncology Disease Oriented Working Group	2003 - 2016
Member, University of Wisconsin Comprehensive Cancer Center	1997 - 2016
Co-chair, Developmental Therapeutics Group	1996 - 2016

University of Wisconsin-School of Pharmacy

Advisor, Student American College of Clinical Pharmacy	2015 - 2016
Member, Academic Progress Committee	2013 - 2016
Vice-Chair, Standards 4-8, Self Study Committee	2010 - 2012
Member, Self Study Steering Committee	2010 - 2012
Member, Curriculum Committee	2010 - 2012
Member, Instrumentation Committee	2009 - 2016
Member, Academic Planning Committee	2009 - 2012
Member, Research Committee	2005 - 2016
Member, Lectures Committee	2003 - 2005
Member, Executive Committee	2002 - 2016
Member, Space Committee	2001 - 2003
Member, Educational Policy and Planning	2000 - 2004
Member, Pharmacy Practice Research Committee	1997 - 2016
Member, Awards and Citations Committee	1996 - 2000
Member, Information Technology Committee	1996 - 1999

FORMER and CURRENT TRAINEES AND JUNIOR FACULTY

Those with current academic positions are underlined

Junior Faculty, Primary Mentor

<u>Nathan Seligson</u> , PharmD, Assistant Professor, Un of Florida	2021 - present
<u>Dan Crona</u> , PharmD, Assistant Professor, UNC	2020
<u>Samuel Awuah</u> , PhD, Assistant Professor, Un of Kentucky	2020 - 2022
<u>Aman Chauhan</u> , MD, Associate Professor, Un Miami	2017 - 2022
<u>Zyint Min</u> , MD, Assistant Professor, Un of Kentucky	2017 - present
<u>Rebecca Marnocha</u> , PharmD, Faculty Review Committee, UW-Madison	2010 - 2011
<u>John Dopp</u> , PharmD, Junior Faculty Review Committee, UW-Madison	2003 - 2012
<u>Uchenna Njiaju</u> , MD Assistant Professor, MD, UW-Madison	2001 - 2003
<u>Julie Chang</u> , MD, Assistant Professor, MD, UW-Madison	2000 - 2016

International Visiting Scientists, Faculty Host and Primary Mentor

<u>Jakapun Yoodee</u> , PhD, Taiwan University	2020
* <u>Vishwapriya M. Godkhindi</u> , MD, Manipal	2019 - 2021 (remote)
* <u>Umesh Velu</u> , MD, Manipal	2019 - 2021 (remote)
* <u>Gayathri Baburaj</u> , PharmD	2019 - 2021 (remote)
<u>Nobuhiko Nakamura</u> , PhD, Kyoto University	2014 - 2015
<u>Ryuji Ikeda</u> , PhD, Kagoshima University	2008 - 2010
<u>Hiro Ikesue</u> , PhD, Kyushu University	2008 - 2009

Postdoctoral Trainees- University of Kentucky

Allison Swiecki-Sikora, MD	2023 - present
*Connie Cao, MD	2022 - present
Taylor Rives, MD	2022 - present
Awards: 3rd Place, Best Postdoctoral Research. Markey Cancer Research Day	2022 - present

Lauren McKenzie Harbin, MD	2021 - present
Namrata Anand, PhD	2021 - present
Awards: 2 nd Place, Best Postdoctoral Research. Markey Cancer Research Day	2022
*David Schweer, MD	2020 - present
Awards: 3rd Place, Best Postdoctoral Research. Markey Cancer Research Day	2022
<u>Megan Hutchcraft, MD</u>	2020 - 2023
Awards: Society of Gynecological Oncology 2022 Best Oral Abstract Award	2022
<u>Alexandra Nail, PhD</u>	2019 - 2020
McKayla Riggs, MD	2019 - 2022
*Justin Gorski, MD	2018 - 2022
Awards: Best Overall Abstract, 2019 GynOnc Live Fellows Forum	2019
Anthony McDowell, MD	2018 - 2021
Brian Burgess, MD	2017 - 2020

Postdoctoral Trainees- UW-Madison

Rachel Leverage, PhD	2012 - 2014
Kamakshi Sachidanandam, PhD	2010 - 2012
<u>Jian Teng, PhD</u>	2007 - 2010
*Kris Hahn, PharmD	2004 - 2007
*Alma Hamidovic, PharmD	2004 - 2006

Graduate Students – Primary Mentor

Spencer Peh, PhD Candidate, University of Kentucky	2021 - present
Award: Pharmaceutical Sciences Graduate Program Student Travel Award	
Award: AFPE Predoctoral Fellow	
Award: Pharmaceutical Sciences Graduate Program Student Travel Award	
Award: ACCP Trainee Award	
Lauren Dietz, MS Candidate, University of Kentucky	2021 - 2023
Award: 2 nd Place, Best Student Research. Markey Cancer Research Day	2022
* <u>Nan Lin, PhD Candidate, University of Kentucky</u>	2019 - 2023
Award: Excellence in Graduate Achievement Fellowship Award	2022
Award: 3rd Place, Best Graduate Student Research. Markey Cancer Research Day	2023
Postdoc: Harvard	2023
*Connie Cao, MD, PhD Candidate, Clinical Investigation	2022 - present
*David Schweer, MD, PhD Candidate, Clinical Investigation	2020 - present
Award: 3rd Place, Best Postdoctoral Research. Markey Cancer Research Day	2022
<u>Megan Hutchcraft, MD, MS Candidate, Clinical Investigation,</u>	2020 - present
Award: Society of Gynecological Oncology 2022 Best Oral Abstract Award	2022
McKayla Riggs, MD, MS Candidate, MS Clinical Investigation,	2022
Bryce Matlock, MS Pharmaceutical Sciences, University of Kentucky	2021
Anthony McDowell, MD, MS Clinical Investigation, University of Kentucky	2021
Brian Burgess, MD, MS Clinical Investigation, University of Kentucky	2020
*Justin Gorski, MD, PhD Clinical Investigation, University of Kentucky	2018 - 2022
Award: Best Overall Abstract, 2019 GynOnc Live Fellows Forum,	2019
<u>Jeff Engle, MS Clinical Investigation, University of Wisconsin</u>	2016
<u>Jessy Van der Em, MS Clinical Investigation, Utrecht, Netherlands</u>	2012
<u>Eveline Wallenberg, MS Clinical Investigation 2012, Utrecht, Netherlands</u>	2012
<u>Willeke Ros, MS Clinical Investigation, Utrecht, Leiden</u>	2012

Graduate Students, Committees Member

*Jennifer Castle, MD, PhD Candidate, Clinical Investigation, Un of Kentucky	2022 - present
Mariah Geisen, PhD Candidate, Toxicology, Un of Kentucky	2022 - present
Tanner DuCote, PhD Candidate, Toxicology, Un of Kentucky	2018 - 2023
Kellar Toral, PhD 2022, Pharmaceutical Sciences, Un of Kentucky	2018 - 2023
<u>Fan Chen, PhD 2020, Toxicology, Un of Kentucky</u>	2017 - 2022
<u>Tingling Zhai, PhD 2020, Statistics, Un of Kentucky</u>	2017 - 2020
Carlos Coriano, PhD 2015, Molecular and Environmental Toxicology, Un of Wisconsin	2011 - 2015
Stephanie Harmon, PhD 2017, Medical Physics, Un of Wisconsin	2014 - 2017
<u>Erin Shanle, PhD 2013, Molecular and Environmental Toxicology, Un of Wisconsin</u>	2009 - 2013

Oncology (PGY2) Resident Trainees (Longitudinal Academic Rotation/Research Mentor)

<u>Kyle Zachloski</u> , PharmD	2018 - 2019
Dan Nichols, PharmD	2017 - 2018
Sara Koth, PharmD	2015 - 2016
<u>Lauren McGinty</u> , PharmD	2015 - 2016
Katherine Croegert, PharmD	2014 - 2015
<u>Jason Bergsbakken</u> , PharmD	2013 - 2014
<u>Jennifer Piccolo</u> , PharmD	2012 - 2013
<u>Kate Simondsen</u> , PharmD	2011 - 2012

Medical Students- Research Mentor-University of Kentucky

Parvane Karimpour, Professional Student Mentored Research Fellowship Program	2022
Carrigan Wasilchenko, Professional Student Mentored Research Fellowship Program	2022
Annabel McAtee, Professional Student Mentored Research Fellowship Program	2021
Jodi DeJohn, Professional Student Mentored Research Fellowship Program	2019

Undergraduate Research Students – University of Kentucky

Rebecca Ahn, Bio 395	2020 - present
Carrigan Wasilchenko, pre-med	2019
Andrew Chen, pharmacy student summer research	2019

High School Students – University of Kentucky

Camari Parker, Appalachia Career Training in Oncology	2023
Holly Burke, Appalachia Career Training in Oncology	2023
Ceana Bays, Appalachia Career Training in Oncology	2022
Chezney Boothe, Appalachia Career Training in Oncology	2022
William Adams, Appalachia Career Training in Oncology	2019
Brianna Reyes, Appalachia Career Training in Oncology	2019
Spencer Shelton, Appalachia Career Training in Oncology	2019
Reka Gal, Dunbar Gifted Students Program	2019 - 2020

**A complete list of former students and trainees with current employment is available upon request*